Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05477563
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2022-07-26
Brief Title:
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Sponsor:
Organization:
Vertex Pharmaceuticals Incorporated